Investor Relations

The cancer treatment paradigm has shifted dramatically over the last decade, providing evidence that the immune system can be reactivated against a patient’s tumor. At Candel Therapeutics, we are developing and commercializing viral immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.